Health AI Central
Peer-Reviewed Publication
Clin Chim Acta2027;593121286.February 15, 2027Journal Article

Comparative evaluation of traditional and novel biomarkers for pulmonary hypertension across clinical subtypes.

Junyi Wu1, Jing Wang2, Jiashu Yang1, Xinyi Rao1, Yan Ma1, Xiao Zhang1, Yi Zhang3, Hui Yuan4
1Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Chaoyang, Beijing, 100029, China.
2Immunoassay Reagent R&D Department, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, 518107, China.
3Immunoassay Reagent R&D Department, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, 518107, China. Electronic address: zhangyi_b@mindray.com.
4Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Chaoyang, Beijing, 100029, China. Electronic address: 18911662931@189.cn.
PubMed DOI

Abstract

OBJECTIVES: This study aimed to compare the auxiliary diagnostic performances of traditional biomarkers, including B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), and novel biomarkers, including N-terminal insulin-like growth factor-binding protein 4, soluble suppression of tumorigenicity 2, and growth differentiation factor 15 (GDF-15), for pulmonary hypertension (PH) and its…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.